Immuron (IMRN) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MetaVia is the larger company by market cap ($9.6 million vs $9.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | IMRN | MTVA |
|---|---|---|
| Share price | $1.11 | $1.46 |
| Market cap | $8.97M | $9.62M |
| 1-day change | +1.99% | 0.00% |
| EPS (TTM) | $-0.34 | $-3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.39 | $14.85 |
| 52-week low | $0.677 | $0.966 |
| Distance from 52-week high | -53.49% | -90.17% |
| Average volume | 2.06M | 230.88K |
| Shares outstanding | 8.07M | 6.59M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
IMRN vs MTVA FAQ
Which is bigger, Immuron or MetaVia?
MetaVia (MTVA) is larger, with a market capitalization of $9.62M compared with $8.97M for Immuron (IMRN).
Are Immuron and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.